2014’s Turkey of the Year

by Travis Johnson, Stock Gumshoe | November 26, 2014 1:01 am

What's the biggest stinker of the last 12 months?

It’s a tradition to give thanks at this time of the year, and one of the things we are supremely grateful for is the never-ceasing parade of promises that the financial newsletter industry throws our way in their perpetual search for new subscribers. After all, without those overhyped promises in their teaser ads we’d have no use for the power of the Mighty, Mighty Thinkolator… think of the mischief that powerful machine would get into without a worthy challenger to keep it busy!

So every year, I look back on our tracking spreadsheets[1] and see which of the terrible teased stock picks catch my eye — the “Turkey of the Year[2]” is not always the absolute worst performing teased stock pick, but it’s among the worst and among the most aggressively hyped… and that’s saying something, since almost every teaser pitch focuses on the potential that a stock might double or triple (or better).

To give you some context, so far in 2014 75% of the teaser stocks we’ve revealed for your edutainment have done worse than the S&P 500. About a third of the stocks are in the green, but unlike past years there’s not a single stock in the teaser tracker[3] that has doubled (or any that have gone down by more than 95% — usually we get at least one bankruptcy or complete washout).

I try not to bestow the title on stocks that we probably knew were total gambles that could evaporate instantly, like junior mining stocks or early stage biotechs, so we’re not calling out Alex Daley[4]’s tease of Prana Biotechnology (PRAN)[5] for Casey[6] Extraordinary Technology, for example, and the wattle does not go to one of the tiny little nanocap stocks like Applied DNA (APDN, teased by Ray Blanco[7] this year and Patrick Cox[8] in past years) that’s probably just as deserving — but after browsing through the last twelve months of teaserdom one stock caught my eye, so this year the “Turkey of the Year” is one that failed not because of a FDA[9] decision that went against them, or a mine that flooded, but because a big new project is starting even more slowly than thought, and, really, the business wasn’t nearly as good as management (or the newsletter) claimed.

And this was not a “flash in the pan” stock that was hinted at once by a small newsletter, it was aggressively teased multiple times by two different established newsletter publishers… and, as coincidence would have it, the stock has been going down for a long time but it really collapsed just in the last few weeks.

So who is our Turkey of the Year? Solazyme (SZYM), teased by both oil[10]-superstar-1-company-pulling-profits-out-of-thin-air/">Motley Fool[11] Hidden Gems[12] last December and by Jimmy Mengel[13]’s The Crow’s Nest just last month.

And really, probably the most egregious (or at least, poorly timed) pitch is Mengel’s for SZYM, since his spiel was based on the fact that you had to get in right away for a windfall from an upcoming announcement…

“Prepare yourself now for a $107,000 windfall…

“But only if you move BEFORE this company’s next big announcement””

That was on on October 1, and a couple weeks ago, on November 5, the announcement did indeed come[14] — but contrary to the promise of a windfall, the announcement was that their revenue was failing to meet expectations, and that future sales would be even more disappointing because of problems ramping up their first huge, commercial plant in Brazil[15]. The Motley Fool quite aggressively teased and touted Solazyme at an even higher price than The Crow’s Nest ($9.50 or so), but they did so much longer ago and didn’t as clearly promise a specific windfall within a short period of time.

Does this mean The Crow’s Nest or Motley Fool Hidden Gems are terrible? Not necessarily, we don’t know what they told their subscribers, or the dozens of other things they might have recommended to their followers beyond the heavily hyped pitches for Solazyme… and everyone, of course, makes mistakes. I make lots of them — I own one of the many other stocks that could have been a contender for “Turkey” this year, East West Petroleum, and have certainly owned or written favorably about many other stocks that have been clobbered over the years. The “Turkey” is Solazyme’s stock, not necessarily the folks who fell in love with it.

And does it mean Solazyme is a lousy stock to buy now? Again, not necessarily — it is a real company, despite the fact that its plant in Brazil is starting up in very disappointing fashion, and it might be that this washout will be enough to right the ship, reset expectations, and give them a chance going forward… they do have some financial flexibility, since they have enough cash on hand to cover their long-term debt, so they shouldn’t be on the verge of bankruptcy, but it is still a very challenging business, reliant on gaining new customers for their high-value-added oils and ramping up what is clearly a complex and challenging process to industrial scale.

There’s no way they can compete in commodity products (like transportation fuels), not with oil prices falling, but despite the past hype for Solazyme as a biofuel company they’ve seen that writing on the wall for a long time and have been focused on nutrition, cosmetics and specialty chemicals… areas with less price-sensitivity for differentiated products, but still extremely competitive markets. So there’s still the hope that the company can find customers… though they obviously have to fix the rampup of the Brazil plant first, and it’s clear that production ramp-up is going to be well below the projections for at least a couple of years.

What it really means, I hope, is that we can take this moment to be thankful for that big old lump of grey matter above our eyeballs — the frontal lobe of our brain that will help us to learn, once again, from the mistakes we make when we allow marketers and promoters to get inside our heads and plant dreams of wealth and windfalls. And when it comes time for our New Year’s resolutions we can resolve to be patient, to think things through, and, when gambling[16] on wild stories and breakthrough dreams, to keep our bets small.

With that, I wish for you a wonderful Thanksgiving holiday… I hope you’re comfortably ensconced with friends, family, and happy memories, and that you can enjoy a nice long weekend of peace before we return to uncover the facts behind the new teasers that will certainly hit your mailbox over the holiday break. See you in December!

P.S. This is obviously very subjective, and based on my thoughts about the pitches of the past year — do you have a better “Turkey” to nominate in the world of teased and promoted stocks? Let us know with a comment below.

Are you getting our free Daily Update
"reveal" emails? If not,
just click here...


Endnotes:
  1. our tracking spreadsheets: http://www.stockgumshoe.com/tracking/
  2. Turkey of the Year: https://www.stockgumshoe.com/tag/turkey-of-the-year/
  3. teaser tracker: http://www.stockgumshoe.com/tracking/
  4. Alex Daley: https://www.stockgumshoe.com/tag/alex-daley/
  5. Prana Biotechnology (PRAN): https://www.stockgumshoe.com/tag/pran/
  6. Casey: https://www.stockgumshoe.com/tag/casey/
  7. Applied DNA (APDN, teased by Ray Blanco: http://www.stockgumshoe.com/reviews/breakthrough-technology-alert/travis-can-you-break-this-please/
  8. Patrick Cox: https://www.stockgumshoe.com/tag/patrick-cox/
  9. FDA: https://www.stockgumshoe.com/tag/fda/
  10. oil: http://www.stockgumshoe.com/reviews/motley-fool-hidden-gems/revealing-the-fools-silicon-valley-a%20href=
  11. Motley Fool: https://www.stockgumshoe.com/tag/motley-fool/
  12. Hidden Gems: https://www.stockgumshoe.com/tag/hidden-gems/
  13. by Jimmy Mengel: http://www.stockgumshoe.com/reviews/crows-nest-the/the-god-complex-and-jimmy-mengels-promise-of-a-107000-windfall/
  14. the announcement did indeed come: http://www.bloomberg.com/news/2014-11-06/solazyme-slumps-most-on-record-on-delays-at-brazil-plant.html
  15. Brazil: https://www.stockgumshoe.com/tag/brazil/
  16. gambling: https://www.stockgumshoe.com/tag/gambling/

Source URL: https://www.stockgumshoe.com/2014/11/2014s-turkey-of-the-year/


20 responses to “2014’s Turkey of the Year”

  1. Tim Carp says:

    SZYM is a good nomination for TOTY. DDD is also a good one as the Fools were still touting buying in when the stock was at the $90 mark.

  2. slowtalker says:

    Do not forget BNIKF!

  3. Bob says:

    talk about turkeys, how’s your favorite SeaDrill doing?

  4. Alan Harris says:

    Ha!!! I vote RGDO. Wipeout !

  5. at_57 says:

    My vote is RIG. Dont expected a 53% drop !!!! Neither Carl Icahn :)))))

  6. bradyoung says:

    I nominate WPRT! Westport cannot seemingly get off its downward slide.

  7. koifish46 says:

    I think the turkey of the year is not a stock but a person. I nominate Money Map Press newsletter writer, Michael Robinson. Last August he promoted Stellar Biotech (SBOTF) and stuck his turkey neck out by guaranteeing that the company would be up listed to NASDAQ or NYSE by the end of November. He stated that if it did not up list by then he would refund the subscription price to those suckers that bought into his hype. I haven’t heard how that went, but would like to know if anyone has the answer.

  8. Jon Stark says:

    GT Advanced Technologies (GTATQ) has to be one of the busts of the year, after Motley Fool was pushing pretty hard for their role in the iPhone 6…and then they go so spectacularly bankrupt

  9. Jeff McDermott says:

    http://www.nasdaq.com/press-release/solazyme-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick–foti-llc-reminds-20150724-00841

    NEW ORLEANS, July 24, 2015 /PRNewswire/ — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have untilAugust 24, 2015 to file lead plaintiff applications in a securities class action lawsuit against Solazyme, Inc. (NasdaqGS:SZYM) if they purchased the Company’s securities between February 27, 2014 and November 5, 2014, inclusive (the “Class Period”), including purchasers in the Company’s registered public offerings on March 27, 2014. This action is pending in the United States District Court for the Northern District of California.

    What You May Do

    If you purchased shares of Solazyme and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by August 24, 2015.

    About the Lawsuit

    Solazyme and certain of its executives are charged with failing to disclose material information during the Class Period and in connection with the March 27, 2014 Offerings, violating federal securities laws.

    Solazyme allegedly made false statements and omissions about its construction progress, development and production capacity at its renewable oils production facility located in Moema, Brazil (the “Moema Facility”), failing to disclose that the Moema Facility was experiencing construction delays due to insufficient access to electricity and steam utility services, and that these challenges would prohibit the Moema Facility from scaling its capacity production as projected.

    On November 5, 2014, the truth regarding the Moema Project was revealed to investors, and the price of Solazyme’s shares plummeted by 58%.

    About Kahn Swick & Foti, LLC

    To learn more about KSF, whose partners include the Former Louisiana Attorney General, Charles C. Foti, Jr., and other lawyers with significant experience litigating complex securities class actions nationwide on behalf of both institutional and individual shareholders, you may visit http://www.ksfcounsel.com.

    Read more: http://www.nasdaq.com/press-release/solazyme-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick–foti-llc-reminds-20150724-00841#ixzz3h103TOUE

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.